Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2026)

Akari Therapeutics (AKTX) has 11 years of Total Non-Current Liabilities data on file, last reported at $19.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 32.66% year-over-year to $19.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (down 32.66% YoY), and the FY2025 full-year result was $19.5 million, down 30.11% from the prior year.
• Total Non-Current Liabilities was little changed at $19.5 million in Q1 2026, from $19.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $28.9 million in Q1 2025 to a low of $2.6 million in Q3 2024.
• A 5-year average of $14.8 million and a median of $19.5 million in 2026 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 983.35% in 2025 and slumped 32.66% in 2026, its largest moves.
• Tracing AKTX's Total Non-Current Liabilities over 5 years: stood at $4.2 million in 2022, then grew by 9.07% to $4.6 million in 2023, then surged by 511.73% to $28.0 million in 2024, then tumbled by 30.11% to $19.5 million in 2025, then dropped by 0.21% to $19.5 million in 2026.
• Business Quant data shows AKTX's Total Non-Current Liabilities at $19.5 million in Q1 2026, $19.5 million in Q4 2025, and $22.6 million in Q3 2025.